How the Life Science Industry Helps in Diagnosis and Treatment of COVID-19 Patients
The life science industry is working tirelessly to ensure immediate diagnosis and treatment against COVID-19. That’s why it is within the public and the public institutions’ best interest to support and amplify life scientists’ voices.
After all, they are working to help find the treatment to get us back to living everyday lives once again.The life science industry has always been a significant part of medical improvements and treatments. These days, the life science industry is front-and-center due to the current pandemic’s severity and urgency.
On that note, here is how the life science industry helps in the diagnosis and treatment of COVID-19:
According to Michelle Dipp, a Life Science expert, the biotech and pharmaceutical industries are at the forefront of the battle against COVID-19. This means that they are responsible for finding treatments against the virus. And this includes clinical trials that are happening worldwide.
Nonetheless, we cannot deny that current practices about clinical trials took a shift because of the urgency of the matter:
Phase 0 is the clinical trial step when the life scientists test the medical solution on people. This phase helps speed up a medical solution’s approval, like a drug or vaccine for COVID-19.
Although scientists test it in humans, the dosage is minimal, and so is the number of people they try. It’s only there to check whether the wanted effect is manifesting in people.
Life scientists rarely use this phase, but they may need to revert to this if they are looking to speed up the production and approval.
Phase 1 is usually the first part of testing humans’ treatment, again in a very low dosage at first. Phase 1 is about identifying the highest dosage that they can apply to patients. Doing so enables them to know when severe side effects are likely to occur.
This phase is when life scientists learn how the body reacts to the treatment and how it affects the body. At this point, though, the disease’s response to the treatment isn’t the priority.
Phase 2 in a clinical trial will have more participants, reaching around several hundred. The participants are currently afflicted with the disease that the new treatment should help cure or alleviate. At this point, the dosage is also still relatively small.
If, in this phase, not too many people suffer from side effects or the side effects aren’t quite severe, the treatment can move onto the next stage.
When the treatment reaches Phase 3, the life scientists will test the treatment against the other treatments already out in the world. They’ll see if the new treatment is as effective or even more effective than those out right now. In this case, usually, the scientists do a double-blind study.
A double-blind study is when the doctor and the patients don’t know which treatment they’re getting.
If the treatment manages to reach Phase 4, that means that the FDA or the Food and Drug Administration has approved the treatment. At this point, doctors are free to administer or prescribe this treatment to their patients because the FDA has approved of it. However, this doesn’t mean that the trial stops.
When treatment is at Phase 4, the study takes longer, and there are thousands of more people getting the treatment. This phase aims to identify the effect of the treatment time on the patient’s health and quality of life.
Understanding the virus
The life sciences industry is also involved in a better understanding of the behaviors of the COVID-19 virus. By knowing the virus’s nature, health systems can identify whether the virus in the body has mutated, spread, or is present.
This information means that it’s a lot faster to find a solution or treatment for the patient. Nowadays, the relevant information is critical towards their chance of getting over the virus.
More life scientists are discussing the virus with both the media, the masses, and government officials.
When the public understands how the virus spreads, they can take the right steps in their day-to-day life. Doing so prevents them from getting infected.
This also ensures that medical institutions and professionals will not be overwhelmed by the increasing number of patients.
Supply of medical products
Right now, supplies for medical products that the life sciences industry creates are focused on the fight against COVID-19. The outbreak is a priority. However, this might mean that there are fewer supplies of medical products unrelated to COVID-19.
Life scientists are doing their best to also supply medical products and treatments for other health problems. However, patients should only remember to buy what they need to stop those who need it most from getting the treatment they need.
Research and development
Research and development are within the expertise of the life sciences industry. That’s why they’re a part of the leading taskforce towards research and development efforts fighting against the virus.
Life scientists equip us with real-time knowledge of the virus, which will help address immediate concerns if they find it.